CoChat

The DOI matches its Crossref record; 60 of the 67 references it cites were found in a registry or an index; 12 of the 35 sources its claims cite were checked for support.

Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials

Open access
Shang, Xue, E, Fen-Fen, Guo, Kang-Le, Li, Yan-Fei, Zhao, Hong-Lin, Wang, Yan, Chen, Nan, Nian, Tao, Yang, Chao-Qun, Yang, Ke-Hu, Li, Xiu-Xia · 2022 · Nutrients

Abstract

To perform a systematic review and meta-analysis to evaluate the effectiveness and safety of probiotics in the treatment of constipation-predominant irritable bowel syndrome (IBS-C), we searched for randomized controlled trials (RCTs) comparing probiotic care versus placebos for patients with IBS-C in five comprehensive databases (March 2022). The risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. RevMan 5.3 was used to perform a meta-analysis on stool consistency, abdominal pain, bloating, quality of life (QoL), fecal Bifidobacterium and Lactobacillus counts, and adverse events. The GRADE approach was used to evaluate the certainty of the evidence. Ten RCTs involving 757 patients were included. Only three studies were rated as having a low risk of bias. The meta-analysis results show that, compared to the placebo, probiotics significantly improved stool consistency (MD = 0.72, 95% CI (0.18, 1.26), p < 0.05, low quality) and increased the number of fecal Bifidobacteria (MD = 1.75, 95% CI (1.51, 2.00), p < 0.05, low quality) and Lactobacillus (MD = 1.69, 95% CI (1.48, 1.89), p < 0.05, low quality), while no significant differences were found in abdominal pain scores, bloating scores, QoL scores, or the incidence of adverse events (p > 0.05). The low-to-very low certainty evidence suggests that probiotics might improve the stool consistency of patients with IBS-C and increase the number of Bifidobacteria and Lactobacilli in feces with good safety. However, more high-quality studies with large samples are needed to verify the findings.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 10 RCTs (757 IBS-C patients) found that probiotics improved stool consistency and increased fecal Bifidobacteria and Lactobacilli versus placebo, with no significant overall effects on abdominal pain, bloating, QoL, or adverse events. Evidence certainty was low to very low, so the authors conclude probiotics may be beneficial and safe but that larger, higher-quality trials are needed.

Key findings

  • Probiotics significantly improved stool consistency versus placebo (MD = 0.72, 95% CI 0.18–1.26, p < 0.05; low quality) and increased fecal Bifidobacteria (MD = 1.75, 95% CI 1.51–2.00, p < 0.05; low quality) and Lactobacillus (MD = 1.69, 95% CI 1.48–1.89, p < 0.05; low quality).
  • No significant overall differences were found for abdominal pain (SMD = −0.28, 95% CI −0.60–0.05, p > 0.05), bloating (SMD = −0.14, 95% CI −0.46–0.18, p > 0.05), QoL (SMD = −3.92, 95% CI −8.09–0.25, p > 0.05), or adverse events (OR = 1.57, 95% CI 0.87–2.82, p > 0.05).
  • Sensitivity analyses for abdominal pain, bloating, and QoL were unstable; after excluding one study, abdominal pain became significant (SMD = −0.20, 95% CI −0.38 to −0.01, p < 0.05, I² = 0%) and bloating became significant (SMD = −0.31, 95% CI −0.61 to −0.02, p < 0.05).
  • GRADE certainty was low for abdominal pain, bloating, stool consistency, adverse events, and fecal Bifidobacteria/Lactobacilli, and very low for QoL.

Methods

  • Systematic review and meta-analysis of randomized controlled trials comparing probiotics versus placebo in patients with IBS-C diagnosed by Rome I–IV criteria; primary outcomes were stool consistency and fecal colony counts, with secondary outcomes of abdominal pain, bloating, QoL, and adverse events.
  • Five databases (PubMed, Embase, Cochrane Library, Web of Science, CBM) were searched from inception to March 2021, updated March 2022; 10 RCTs with 757 patients were included.
  • RevMan 5.3 was used for meta-analysis with MD, SMD, or OR and 95% CIs; heterogeneity was assessed with χ² and I², and the Cochrane Risk of Bias Tool and GRADE were used for quality and certainty assessment.

Limitations

  • The authors state that only English-language reports were covered, which may have led to language bias; results are based only on currently published literature; and most studies reported multiple probiotic mixtures, so specific strains could not be analyzed.
  • The paper reports that only 3 of 10 RCTs were rated low risk of bias, while 7 were unclear, mainly due to incomplete reporting of random sequence generation, allocation concealment, and blinding.
  • The text makes evident additional limitations: small sample sizes, statistical heterogeneity in abdominal pain, QoL, and bloating, unstable sensitivity analyses, and no publication bias detection because all outcomes had fewer than 10 studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu14122482

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow diagram of the literature screening process and results.
Figure 1 Flow diagram of the literature screening process and results.CC BY · PubMed Central
Figure 2 Risk of bias assessment for the included studies [49,50,51,52,53,54,55,56,57,58].
Figure 2 Risk of bias assessment for the included studies [49,50,51,52,53,54,55,56,57,58].CC BY · PubMed Central
Figure 3 Effect of probiotics on stool consistency scores in IBS-C patients. The blue block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 3 Effect of probiotics on stool consistency scores in IBS-C patients. The blue block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central
Figure 4 Effect of probiotics on changes in fecal counts of Bifidobacterium and Lactobacillus in IBS-C patients. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 4 Effect of probiotics on changes in fecal counts of Bifidobacterium and Lactobacillus in IBS-C patients. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central
Figure 5 Effect of probiotics on abdominal pain scores in IBS-C patients. (a) subgroup analysis for abdominal pain scores; (b) sensitivity analysis for abdominal pain scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 5 Effect of probiotics on abdominal pain scores in IBS-C patients. (a) subgroup analysis for abdominal pain scores; (b) sensitivity analysis for abdominal pain scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central
Figure 6 Effect of probiotics on bloating scores in IBS-C patients. (a) subgroup analysis for bloating scores; (b) sensitivity analysis bloating scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 6 Effect of probiotics on bloating scores in IBS-C patients. (a) subgroup analysis for bloating scores; (b) sensitivity analysis bloating scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central
Figure 7 Effect of probiotics on quality of life (QoL) scores in IBS-C patients. (a) subgroup analysis for QoL scores; (b) sensitivity analysis for QoL scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 7 Effect of probiotics on quality of life (QoL) scores in IBS-C patients. (a) subgroup analysis for QoL scores; (b) sensitivity analysis for QoL scores. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central
Figure 8 Effect of probiotics on incidence of adverse events in IBS-C patients. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.
Figure 8 Effect of probiotics on incidence of adverse events in IBS-C patients. The green block represents the effect sizes of individual studies, black diamond block represents the combined effect size.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 0 Not valid · 7 Not checked · 83 Own results and interpretations

60 more claims

Create a free account to see all 97 claims and to verify the 7 references still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 60 references

Research works printed but not linked: 3

  1. Hu, 2012, The changes and significances of intestinal microflora in patients with irritable bowel syndrome, Acta Univ. Med. Anhui, 47, 86
  2. Jang, 2012, Therapeutic efficacy of probiotics and analysis of intestinal flora in patients with irritable bowel syndrome, Chin. J. Clin. Healthc., 15, 132
  3. Thompson, 1989, Irritable bowel syndrome: Guidelines for the diagnosis, Gastroenterol. Int., 2, 92

Cited by

See all 41

Metadata

Authors
Shang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., & Li, X.-X.
Affiliations
  • Lanzhou University (CN)
  • Health Technology Assessment Center, Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, China
  • Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
  • Institute of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou 730000, China
Venue
Nutrients
Publisher
MDPI AG
Published
2022-06-15
Volume
14
Issue
12
Pages
2482
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4283034610
Cited by
41
References
67
Citations by year
2026: 7 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 2
FWCI
1.75
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lanzhou University Institutional Repository (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
  • Gansu Special Project of Soft Science (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
  • Fundamental Research Funds for the Central Universities (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, irritable bowel syndrome with constipation, stool consistency, abdominal pain, bloating, quality of life, adverse events, probiotic safety
MeSH terms
Bifidobacterium, Constipation, Flatulence, Humans, Lactobacillus, Abdominal Pain, Randomized Controlled Trials as Topic, Treatment Outcome, Probiotics, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. https://app.cochat.ai/papers/10.3390/nu14122482
The paper
Shang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., & Li, X.-X. (2022). Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. Nutrients. https://doi.org/10.3390/nu14122482

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.